Victory Capital Management Inc. Purchases 45,395 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Victory Capital Management Inc. raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.0% in the third quarter, HoldingsChannel reports. The fund owned 2,360,762 shares of the company’s stock after purchasing an additional 45,395 shares during the quarter. Victory Capital Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $47,687,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cromwell Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares during the period. Advisors Asset Management Inc. bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $41,000. Rothschild Investment LLC increased its stake in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after purchasing an additional 1,348 shares in the last quarter. JFS Wealth Advisors LLC raised its holdings in Teva Pharmaceutical Industries by 257.1% during the third quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. Finally, LRI Investments LLC raised its holdings in Teva Pharmaceutical Industries by 246.0% during the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after buying an additional 2,000 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Finally, Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $31.06 on Friday. The firm has a 50-day moving average of $33.01 and a 200-day moving average of $26.26. The company has a market cap of $35.71 billion, a P/E ratio of 25.88, a P/E/G ratio of 10.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the company earned $0.71 earnings per share. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 77,400 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the transaction, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Richard D. Francis sold 442,935 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the sale, the chief executive officer directly owned 642,099 shares of the company’s stock, valued at $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 1,210,805 shares of company stock worth $38,221,390. Corporate insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.